Wordt geladen...
EGFR inhibitor gefitinib prevents progression of pancreatic lesions to carcinoma in a conditional LSL-Kras(G12D/+) transgenic mice model
Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy with a dismal prognosis. Developing novel strategies to prevent/delay pancreatic cancer is currently of intense interest. The chemopreventive efficacy of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor,...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2010
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3058550/ https://ncbi.nlm.nih.gov/pubmed/21084261 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-10-0038 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|